18F‑alfatide positron emission tomography may predict anti‑angiogenic responses

  • Authors:
    • Jie Liu
    • Dongxu Wang
    • Xue Meng
    • Xindong Sun
    • Shuanghu Yuan
    • Jinming Yu
  • View Affiliations

  • Published online on: September 10, 2018     https://doi.org/10.3892/or.2018.6692
  • Pages: 2896-2905
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

As the crucial issue in the development of anti‑angiogenic drugs is how to predict which patients will and will not benefit prior to the initiation of therapy, angiogenic 18F‑alfatide positron emission computed tomography (PET) was assessed in the present study. Lung adenocarcinoma A549 (high angiogenesis) and prostate PC‑3 (low angiogenesis) cell xenografted tumor‑bearing mice underwent 18F‑alfatide PET at baseline and following treatment with either an anti‑angiogenic therapy or vehicle. The evaluation index for the inhibition of tumor growth in the individuals in the treated groups was represented by treatment/control (T/C) ratio (%). Anti‑angiogenic responses were denoted by the changes in 18F‑alfatide uptake in the same animal. The T/C ratio was lower in high‑uptake tumors than in low‑uptake tumors (P=0.001). A significant difference in the tumor volumes between the anti‑angiogenic therapy group and the control group occurred earlier in the A549 model than in the PC‑3 model. 18F‑alfatide uptake decreased more for A549 tumors than for PC‑3 tumors following anti‑angiogenic therapy. In each treatment group, the degree of tumor response to anti‑angiogenic therapy was associated well with the tumor uptake prior to treatment (P<0.05). These results indicated that 18F‑alfatide PET may be a useful molecular imaging tool for individual selection prior to anti‑angiogenic drug therapy.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 40 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu J, Wang D, Meng X, Sun X, Yuan S and Yu J: 18F‑alfatide positron emission tomography may predict anti‑angiogenic responses. Oncol Rep 40: 2896-2905, 2018
APA
Liu, J., Wang, D., Meng, X., Sun, X., Yuan, S., & Yu, J. (2018). 18F‑alfatide positron emission tomography may predict anti‑angiogenic responses. Oncology Reports, 40, 2896-2905. https://doi.org/10.3892/or.2018.6692
MLA
Liu, J., Wang, D., Meng, X., Sun, X., Yuan, S., Yu, J."18F‑alfatide positron emission tomography may predict anti‑angiogenic responses". Oncology Reports 40.5 (2018): 2896-2905.
Chicago
Liu, J., Wang, D., Meng, X., Sun, X., Yuan, S., Yu, J."18F‑alfatide positron emission tomography may predict anti‑angiogenic responses". Oncology Reports 40, no. 5 (2018): 2896-2905. https://doi.org/10.3892/or.2018.6692